The UK and US have established a significant bilateral deal that will keep no tariffs on British pharmaceutical exports going into the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase funding on pharmaceuticals through the public health system. This pledge secures that import taxes on these crucial exports will stay at nothing for a duration of three years.
This development is in response to previous threats to dramatically increase tariffs on patented pharmaceutical products, with potential rates floated as high as one hundred percent.
"This deal between the Britain strengthens the worldwide climate for cutting-edge drugs and establishes long-overdue equity to U.S.–U.K. medicine commerce," an announcement said.
Economic Impact
Pharmaceuticals represent one of the the United Kingdom's biggest goods shipped to the US, which is easily the biggest destination for major UK drugmakers.
Statistics reveal that in the 12 months to the end of last September, the UK sold drugs valued at over eleven billion pounds to the US. This figure represented 17.4% of total UK exports in that timeframe.
"This guarantee secures work, stimulates funding and facilitates the UK to emerge as a international leader for medical research," the Business and Trade Secretary remarked.
Specific British Pledges
The deal involves several specific changes from the UK:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new medicines to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to double overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be limited at 15%. Previously, rebates were more than twenty percent.
Industry Background
The deal takes place against a protracted tension between the drug companies and the UK government over drug pricing and approval rates.
These tensions were intensified by claims that American consumers were charged significantly more for the identical medicines than patients in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar expansions have been announced toward projects in the United States.
One official publicly accepted that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had shrunk as a share of its overall budget over the past decade.
